Lesley Seymour
Queen's University
H-index: 79
North America-Canada
Top articles of Lesley Seymour
Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop …
JCO Precision Oncology
2024/4
Essai randomisé contrôlé comparant l’association pembrolizumab plus chimiothérapie à la chimiothérapie seule dans le mésothéliome pleural avancé, non prétraité (essai IND. 227 …
Revue des Maladies Respiratoires Actualités
2024/1/1
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
The Lancet
2021/8/28
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
bmj
2023/10/20
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance
bmj
2023/10/20
Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data
Clinical Lung Cancer
2023/9/1
Prashanth Ashok Kumar
H-Index: 3
Maryam Karimi
H-Index: 0
Lesley Seymour
H-Index: 44
Robert Kratzke
H-Index: 29
IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): a CCTG, NCIN, and …
2023/6/10
Accrual of adolescents and young adults (AYA) into cancer clinical trials in Canada.
2023/6/1
Lesley Seymour
H-Index: 44
A phase II study of durvalumab re-treatment+/-prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND. 238A).
2023/6/1
Response to a Letter Received Entitled:“‘Brief Report: Canadian Cancer Trials Group IND. 227’: Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced …
Journal of Thoracic Oncology
2023/6/1
Penelope Bradbury
H-Index: 23
Lesley Seymour
H-Index: 44
Brief report: canadian cancer trials group IND. 227: A phase 2 randomized study of pembrolizumab in patients with advanced Malignant pleural mesothelioma (NCT02784171)
Journal of Thoracic Oncology
2023/6/1
Towards evidence-based response criteria for cancer immunotherapy
2023/5/24
Lesley Seymour
H-Index: 44
Elisabeth De Vries
H-Index: 68
Abstract P3-07-18: CCTG IND. 239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC)
Cancer Research
2023/3/1
Abstract P3-07-14: A phase II study of CFI-400945 in patients with advanced/metastatic cancer: Canadian Cancer Trials Group (CCTG) IND. 237
Cancer Research
2023/3/1
Abstract P3-07-10: CCTG IND. 236: A Phase 1b trial of combined CFI-402257 and weekly paclitaxel in patients with HER2-negative (HER2-) advanced breast cancer (aBC)
Cancer Research
2023/3/1
Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study.
2023/2/20
Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response
Clinical Cancer Research
2023/1/4
Ronald Boellaard
H-Index: 58
Lesley Seymour
H-Index: 44
Oncology phase I trial design and conduct: time for a change-MDICT Guidelines 2022
2023/1/1
Complementary medicine use amongst patients with metastatic cancer enrolled in phase III clinical trials
The Oncologist
2022/3/1
Jeremy Shapiro
H-Index: 24
Lesley Seymour
H-Index: 44
iRECIST and atypical patterns of response to immuno-oncology drugs
2022
Lesley Seymour
H-Index: 44
